Clinical Trial: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416695) titled 'A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC' on Feb. 11.

Brief Summary: This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3901 in patients with Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: SCLC NEC

Intervention: DRUG: HLX3901

* HLX3901 will be administered as an intravenous (IV) infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Henlius Biotech

D...